CELLESTIA

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)... Based on more than 10 years of academic research led by the company's CEO, Rajwinder Lehal, Cellestia was founded in 2014 as spin-off from the prestigious Swiss Institute for Experimental Cancer Research (ISREC), based at the École Polytechnique Fédérale de Lausanne (EPFL), a world-renowned centre of excellence in Switzerland. Originally incubated at ISREC, today Cellestia has established its independent research facilities at Biopôle in Lausanne and in close proximity to Ludwig Institute for Cancer Research, Swiss Cancer Center Léman, Le Centre hospitalier..

Also known as: CELLESTIA BIOTECH, CELLESTIA BIOTECH AG

Primary location: Basel Belgium